Skip to search formSkip to main contentSkip to account menu

Betaseron

Known as: Beta Seron, Beta-Seron 
National Institutes of Health

Related topics

Related topics

5 relations
Betaferoninterferon beta-1b 0.3 MG Injection [Betaseron]

Broader (3)

Interferon-betaRecombinant Interferon Betainterferon beta-1b

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Cellular self-assembly into 3D microtissues enhances the angiogenic activity and functional neovascularization capacity of human cardiopoietic stem cells
While cell therapy has been proposed as next-generation therapy to treat the diseased heart, current strategies display only… 
Highly Cited
2016
Highly Cited
2016
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial
Objective: To assess outcomes for patients treated with interferon beta-1b immediately after clinically isolated syndrome (CIS… 
Review
2006
Review
2006
Quality Assessment in Multiple Sclerosis Therapy (QUASIMS)
Interferon beta (IFNβ) preparations are the most frequently prescribed therapies for patients with relapsing multiple sclerosis… 
Highly Cited
2005
Highly Cited
2005
Eight-year immunogenicity and safety of interferon beta-1a-Avonex®treatment in patients with multiple sclerosis
An open-label extension study of the phase III trial of intramuscular interferon beta-1a (IFNβ-1a-Avonex) was conducted to… 
Review
2001
Review
2001
A prospective, open-label treatment trial to compare the effect of IFNβ-1a (Avonex®), IFNβ-1b (Betaseron®), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple…
We previously reported results of a 12 month prospective, non-randomized, open-label treatment trial of immunomodulatory therapy… 
Review
2001
Review
2001
A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple…
A prospective, non-randomized, open-label treatment trial was performed in patients with relapsing-remitting multiple sclerosis… 
Highly Cited
1998
Highly Cited
1998
Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and AVONEX.
  • G. Williams, P. Witt
  • Journal of interferon & cytokine research : the…
  • 1998
  • Corpus ID: 45613220
The aim of this 1 week study was to compare the biologic effects induced by Betaseron and AVONEX using their approved dose, route… 
1997
1997
Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: Plight of the practicing neurologist
The recently reported decrease in beta interferon (IFNβ) efficacy induced by anti-IFNβ antibodies1 has prompted Berlex… 
1996
1996
Detection of altered T helper 1 and T helper 2 cytokine production by peripheral blood mononuclear cells in patients with multiple sclerosis utilizing intracellular cytokine detection by flow…
Production of T helper 1 and T helper 2 cytokines was investigated in peripheral blood mononuclear cells (PBMCs) from multiple… 
1995
1995
The use of Zwittergent 3-14 in the purification of recombinant human interferon-beta Ser17 (Betaseron).
A new method for purifying human interferon-beta SER17 from E. coli-derived inclusion bodies has been developed. This procedure… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License